Calyxt, Inc. Stock News

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtu...

Cibus, Inc. (NASDAQ:CBUS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Carlo Broos - Interim CFO Peter Beetham - Co-Founder, Interim CEO, President, COO & Director Gregory Gocal - Co-Founder, Chief Scientific Officer & EVP Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Matthew Venezia - AGP O...

Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture a nd Livesto...

Designation confirms conventional regulation of Cibus herbicide tolerance traits in Rice in Ecuador paving the way for further product development and eventual commercialization in a key Rice growing region Designation confirms conventional regulation of Cibus herbicide tolerance traits in Rice in Ecuador paving the way for further product development and eventual commercialization in a key Ric...

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call...

Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally

Cibus, Inc. (NASDAQ:CBUS ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Carlo Broos - Interim Chief Financial Officer Peter Beetham - Co-Founder, President and COO, Interim CEO Greg Gocal - Co-Founder and Chief Scientific Officer and Executive Vice President Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H...

A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state